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Introduction
Hypersensitivity pneumonitis (HP), also known as extrin-
sic allergic alveolitis, is one of the most common interstitial 
lung diseases (ILDs)1,2. This particular ILD is characterized 
by exposure to an inhaled inciting antigen that leads to a host 
immunologic reaction determining interstitial inflammation 
and architectural distortion. The underlying pathogenetic 
mechanisms are still unclear, showing features of both type 
III and type IV hypersensitivity responses3,4. The sensitization 
process to the inciting antigen plays a pivotal role, turning a 
two-hit hypothesis in the most probable one (Figure 1).
HP epidemiology results to be challenging to determine 
considering the influence of many host, geographic and so-
cial factors5, also few cohort studies are reported in literature. 
But recently a one-year prevalence of 1.67–2.71 per 100,000 
persons and a 1-year cumulative incidence of 1.28–1.94 per 
100,000 persons were reported in a large American popu-
lation6. With a 28% of 4-year mortality and a 52% of 7-year 
mortality fibrotic-HP6, the form with the worst prognosis, 
shows to have a better prognosis than idiopathic pulmonary 
fibrosis (IPF)7,8, but still a worse one when compared to some 
neoplastic conditions, such as thyroid, prostate and colorectal 
cancer9.
Furthermore, the absence of widely shared diagnostic 
guidelines and the lack of a “gold-standard” test for HP com-
bined with the presence of several clinical and radiological 
overlapping features makes it particularly challenging to dif-
ferentiate HP—mostly in its chronic and fibrotic form—from 
other ILDs, such as IPF10. 
Therapeutic options for HP were limited to immunosup-
pressant drugs in the last decades, but recently the effect of 
nintedanib and pirfenidone has been tested with promising 
results in patients with chronic-HP (cHP). 
This review aims to clarify the current state of the art of diag-
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nosis and management of HP.
Diagnosis
1. Medical history and antigen exposure
HP seems to affect more often non-smoker elderly women6, 
even if epidemiologic data are contrasting, mostly regarding 
gender prevalence2,11-13. Several cases were reported also in 
children14 and among teenagers accustomed to vaping15. Ciga-
rette smoke seems to have a double role in HP, it protects from 
developing the disease16, but if there is a positive smoking his-
tory it worsens the prognosis17. Several studies also reported a 
male predominance among HP subjects2,11-13. 
Furthermore, other host factors may play a role in HP de-
veloping process. Just a minority of the subjects exposed to 
inciting antigens develop the disease, proofing that some sort 
of genetic predisposition is involved in the process18-21. Lopez 
and Salvaggio22 showed that just 5%–15% of the subjects with 
known exposure to inciting agents developed HP. 
Another fundamental factor is the host work-related ex-
posure. HP was firstly reported as Farmer’s Lung in the early 
decades of the 20th century, making it clear that some class of 
workers are more prone to develop this disease. Among the 
others, we may find farmers, machinists, factory workers, and 
pigeon breeders23. Other environmental exposures, such as 
the possession of a pet-bird or an indoor hot-tub, significantly 
increase the likelihood of HP diagnosis. The main classes of 
inciting antigens are bacteria, fungus, mycobacteria, avian-
proteins, and chemical products.
HP symptomatology is aspecific and overlaps with several 
conditions, being characterized by shortness of breath, acute 
or slightly worsening, dry cough, malaise, fatigue, loss of appe-
tite, chills, fever, etc. 
Historically HP was classified into three categories acute, 
subacute and chronic; this classification was based both on 
symptoms behavior and disease course. While a recently pro-
posed one, in order to solve some phenotype’s overlap mostly 
between the subacute and the chronic form, promotes the 
presence of only two categories: the acute/inflammatory HP 
(aHP) and the chronic/fibrotic (cHP)24,25.
Influenza-like symptoms (i.e., fever, chills, cough, acute 
dyspnea, etc.) are more common in aHP; symptomatology 
usually begins a few hours following the antigen exposure and 
it may both last or increase over hours or days23,25. Similarly to 
what happens in working-related asthma, in aHP symptoms 
mostly decrease in presence and intensity after a suitable pe-
riod of avoidance of the exposure and may proof, in this way, a 
causal link between expositions and symptomatology.
While cHP is characterized by a sneaky debut of symptoms 
characterized by slightly worsening dyspnea, dry chough, 
malaise, fatigue, loss of appetite23,25, that makes this form of the 
disease on a clinical standpoint very similar to other fibrotic 
ILDs and particularly similar to IPF. Repetitive and low-dose 
antigen exposure is the most common cause of cHP forms26.
The research of an inciting antigen may often be tricky: the 
percentage of cases with successful identification of the caus-
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Figure 1. Immune response in Hypersensitivity Pneumonitis. Characterized by sensitization and immune memory formation (A), acute/sub-
acute inflammation (B), and chronic inflammation (C).
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ative antigen stands below 40%27. Several methods were sug-
gested in order to find it, such as questionnaires, precipitins, 
lymphocyte proliferation test and specific inhalation challenge 
(SIC), but none of those reached large consensus28. These 
methods present limited availability, lack of standardization 
and some of them may result in pretty expensive. There is also 
restricted amount of information about tests’ characteristics, 
mostly regarding SIC. 
2. Pulmonary function tests
Pulmonary function tests (PFTs)—as for every ILD—may 
reveal functional impairment and guide clinicians through pa-
tient management. Global spirometry and diffusing capacity 
of carbon monoxide (TLco) are useful non-invasive methods 
to determine disease course and loss of lung function. TLco 
and forced vital capacity (FVC) decline over time are predic-
tive factors of survival in HP patients29,30. TLco particularly 
may predict exercise impairment being the most sensitive 
functional abnormality31,32. HP-related histologic changes, 
indeed, reduce gas exchange’s area and influence pulmonary 
distension. A >10% FVC decline over 6–12 months showed 
to be a good predictor of worse prognosis33. However, when 
fibrosis is present, PFTs may be insensitive to detect small air-
way involvement34. 
Both aHP and cHP are characterized by gas exchange im-
pairment35,36. 
Besides the acknowledged utility, PFTs may not differenti-
ate HP from the other ILDs37.
3. Radiology
Nowadays high resolution computed tomography (HRCT) 
plays a role of growing interest in HP diagnostic process and 
patient management. It is also recognized as the tool capable 
to identify HP findings with the highest sensitivity34. 
The main findings of aHP are multifocal and diffuse ground-
glass opacities (GGO), centrilobular GGO, signs of air trapping 
on expiratory phases studies and “headcheese sign.” This last 
sign is characterized by the contiguity of lobular areas with dif-
ferent attenuation levels (low, normal or high), which reflect 
heterogenous processes such as GGO, reticulation or fibrosis 
(high attenuation), normal parenchyma (normal attenuation) 
and air trapping (AT) (low attenuation)38. 
The heterogeneity of HP, with both obstructive processes 
(small airways’ obstruction) and infiltrative ones (interstitial 
phlogosis)38, is exemplified by the headcheese sign (Figure 2) 
and mosaic attenuation (MA). HRCT is useful to identify lo-
calized disease-related impairments and airway involvement. 
Among the ILDs HP is the one that more extensively exhibits 
MA, turning it into a prominent feature of HP39. 
The main findings of cHP are architectural distortion, re-
ticular opacities, peribronchovascular interstitial thickening, 
ill-defined centrilobular GGO, MA pattern, upper and middle 
zone predominance, sparing of basal lung areas and traction 
bronchiectasis, honey combing (HC) may be present (Figure 
2)34. At its most advanced stages of disease cHP might show 
radiologic pattern hard to differentiate from either fibrotic 
nonspecific interstitial pneumonia (NSIP) or usual interstitial 
pneumonia (UIP) with HC. The differential diagnosis of HP 
with other ILDs might be tricky also because of these similari-
Figure 2. Radiologic appearance of chronic hypersensitivity pneumonitis at chest high resolution computed tomography. In the inspiratory 
scans (A–D) architectural distortion, reticular opacities, peribronchovascular interstitial thickening ground-glass opacities and traction bron-
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ties40-42, mostly in cases where there is no identification of the 
inciting antigen.
Rarer are the cases in which cysts and emphysema are 
recognized on the chest computed tomography scans of HP 
patients, but they are still possible radiologic features of this 
heterogenous condition43,44. 
Recently great attention was put on radiologic features of 
HP with different studies focusing on HRCT prognostic and 
diagnostic role. The great majority of the studies used a quali-
tative approach34, opening the door analysis’ bias. 
Salisbury et al.45 developed a radiologic predictive model for 
HP diagnosis. Their analysis enlightened that when a major 
extension of AT and MA compared to that of reticulation is 
present, combined to a diffuse axial distribution, there is less 
than 10% chances to make a false-positive diagnosis of HP45. 
Silva et al.41 explored the role of HRCT in solving the challenge 
of differential diagnosis among HP, IPF, and other ILDs. A 
confident differentiation between these different entities was 
possible in nearly half of the cases, underlying once again how 
tricky it may be relying just on radiologic findings for differen-
tial diagnosis. Barnett et al.42 recently focused their attention 
on MA and its role in the differential diagnosis with IPF. The 
presence of the headcheese sign resulted a more confident 
feature to lead to differentiation between cHP and IPF than 
just the extension of MA, challenging the faith of the scientific 
community42,46.
Some studies were performed in order to highlight the prog-
nostic role of radiologic features in HP. Chung and coworkers 
showed how the presence of AT and MA in cHP subject may 
positively influence the survival47. Salisbury et al.48 successfully 
identified three unique radiologic groups of HP patients with 
different prognostic outcomes. The presence of HC in cHP 
determined a prognosis superimposable to the IPF one, worse 
than the prognosis of patients with just cHP; as expectable, pa-
tients without fibrotic changes were the group characterized 
by the better prognosis48. This radiologic phenotypes seems 
easy to adopt and useful in stratifying HP patients49.
The quantitative analysis through the CALIPER software 
was the fundament of Jacob and coworkers’ study50. This is 
one of the few studies relying on quantitative analysis meth-
ods in HP. The main findings of this work were that the auto-
mated analysis performed better than visual scores and was 
able to stratify HP population based on pulmonary vessel 
volume (PVV). Patients with cHP and a high PVV presented a 
prognosis similar to IPF patients50.
4. Bronchioalveolar lavage
The use of the bronchoalveolar lavage (BAL) technique is 
pretty common in the ILD field, even more after the release 
of the last guidelines for IPF diagnosis51. American Thoracic 
Society (ATS) already addressed this issue in 2012, when an 
official guideline about the clinical utility of BAL fluid (BALF) 
analysis in ILD was released52. BAL is often performed in HP 
patients both in the acute and in the chronic forms. Several 
studies reported data about BALF cellularity in these condi-
tions30. By the way, it is still unclear the role of BAL both in HP 
diagnostic process and in HP patients’ management.
Lymphocytosis is, doubtless, the BALF parameter more of-
ten taken into account in HP studies and diagnostic predictive 
models. A higher percentage of lymphocyte in BAL may be a 
positive predictor of HP diagnosis, even if a BALF lymphocytic 
profile may be found also in sarcoidosis, NSIP, and organizing 
pneumonia52. Higher levels of lymphocytosis (>30%–40%) 
seem to better correlate with aHP. While cHP may show a 
slightly increased lymphocytic count (>20%) or even a normal 
one, mostly in patients with radiologic UIP53,54. Some authors 
argue that a higher lymphocytic count may be a positive pre-
dictive factor for survival, considering those forms of HP acute 
ones and more prone to disease resolution55 and response to 
corticosteroid treatment56. On the other hand, a BAL lympho-
cytosis >30% seems to be a useful tool in the tricky differential 
diagnosis between cHP and IPF, making IPF diagnosis very 
unlikely in such a scenario57. 
Besides all the efforts widely shared thresholds for BAL lym-
phocytosis have not been identified yet25,28. 
Also the study of T cells population was carried on HP pa-
tients’ BALF, but not definitive findings supporting its use in 
daily clinical practice have been made25,52. Patients with aHP 
seem to have a higher percentage of CD8+, which lowers after 
exposure avoidance, at the same time patients with cHP seem 
to have a CD4+ predominance58,59. When talking about the 
CD4/CD8 ratio, a nonspecific and insensitive trend towards 
lower levels seems to characterize HP25,52,54. 
5. Histology
The integration of clinical, radiologic and pathologic find-
ings remains the gold standard for the diagnosis of every sub-
type of ILD, but recently we are moving toward a world where 
less invasive procedures are performed on patients. Con-
stantly growing importance is given to radiologic features, that 
in several cases may guide clinicians to a confident diagnosis 
even in the absence of histopathologic specimens. 
Surgical lung biopsy (SLB), as for the other ILDs, is the gold 
standard for tissue sampling60, besides complications related 
to this invasive procedure. Other systems like transbronchial 
biopsies and transbronchial criobiopsies have been proposed 
as alternatives, but no formal validation and/or international 
consensus was reached about their use in the diagnostic pro-
cess of ILDs51,61,62.
Being HP a condition with heterogenous histologic altera-
tions SLB providing a greater amount of tissue should prob-
ably be the elective tissue sampling procedure in order to have 
more chances to find the most characteristic lesions.
The classic histologic triad of HP is composed by peribron-
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chiolar diffuse interstitial inflammatory infiltrates, chronic 
bronchiolitis and peribronchiolar giant cells (with or without 
non-caseous and non-necrotic granulomas) (Figure 3)63-65. In 
the latest stages of disease also UIP may be found. 
Histology also plays a role in the prognostic stratification of 
HP subjects. The UIP pattern, when found, correlates with a 
worse prognosis29. Also airway centered fibrosis and fibrotic 
NSIP show a worse prognosis when compared to peribron-
chiolar inflammation with poorly formed granulomas and cel-
lular NSIP66.
6. Actual diagnostic models and lack of consensus
Some predictive and diagnostic models were recently 
proposed to facilitate clinicians in the hard task represented 
by making a confident HP diagnosis24,25,28,37,67. None of them 
reached a wide consensus, but at least they aroused efferves-
cent discussions about this topic68-71. And nowadays both the 
ATS and the American College of Chest Physicians (ACCP) 
are promoting initiatives aimed to draft clinical evidence-
based guidelines for HP46,70. 
Walsh and coworkers perfectly painted how challenging 
it may be reaching consensus about HP diagnosis72. In their 
study the inter-multidisciplinary team (MDT) agreement for 
HP diagnosis was incredibly poor, making it clear to everyone 
that even clinicians with a proven expertise in the ILD field 
may find it difficult to make HP diagnoses that meet the con-
sensus of the other groups. 
Furthermore, different groups of experts are also propos-
ing different classifications of the disease making the HP field 
even more chaotic. We are all used to the historical classifica-
tion with the three forms of HP: acute, subacute and chronic. 
That was recently overtaken by a more simplistic and binary 
one: aHP and cHP. This one, thus appearing too simple, seems 
to be useful30 and also supported by recent radiologic find-
ings48,49. 
One of the key points of HP diagnosis, in patients with 
compatible respiratory symptoms, is the recognition of the 
inciting antigen. All the proposed diagnostic models agreed 
on that. A careful clinical history should be collected and it is 
fundamental for HP diagnosis, nevertheless in several cases 
the inciting antigen may remain elusive27. The IPF guidelines 
and Fleischner Society’s White Paper also suggest as one of 
the very first steps of the diagnostic process to check for pos-
sible exposures in patients suspected to have IPF, being HP a 
possible alternative diagnosis51,73. Vasakova et al.25 developed 
an exhaustive questionnaire, but it is still lacking of formal 
validation. The same group of authors proposed the definition 
of “cryptogenic HP” for all those cases of truly unknown origin, 
but this terminology was strongly criticized70,74.
All the available diagnostic models also agree about the 
absence of a “gold standard” test for HP diagnosis. However, 
radiology is nowadays having a pivotal role in the diagnostic 
algorithm of ILDs and HP is not excluded. Radiologic findings 
may indeed guide the diagnostic process towards other steps, 
such as what happens in IPF24. Radiologic features like exten-
sive MA were typically thought to be expression of HP: Fleis-
chner Society’s White Paper reported “extensive” MA as most 
consistent with cHP than IPF73, while the last international 
guidelines indicate that “marked” MA should arise the doubt 
of IPF alternative diagnosis51. However recently we witnessed 
an attempt to change of perspectives when the headcheese 
sign was proposed as specific for cHP and inconsistent with 
IPF42. The more relevant role undertaken by HRCT leads to a 
minor rate of invasive procedures’ execution, similarly to what 
happens with IPF tissue sampling is always less common such 
as BAL. These procedures are often relegated to the more 
challenging cases when, lacking the inciting antigen’s identifi-
cation and typical radiologic pattern, the diagnosis’ confidence 
is low. 
As previously reported, lymphocytosis is a characteristic 
finding in HP patients, nevertheless no shared threshold for it 
has been defined yet. Morisset and coworkers in their modi-
fied DELPHI survey reported consensus among international 
Figure 3. Histopathologic aspect of chronic Hypersensitivity Pneumonitis (cHP) at hematoxylin and eosin stain: fibrosis with micro-honey-
combing, non specific chronic inflammation with peri-bronchial and centrilobular distribution (A, B) and multiple non-caseating giant cell 
granulomas (C).
A B C
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experts for high confidence HP diagnosis without the execu-
tion of lung biopsy in the right clinical contest (recognized ex-
posure and HRCT consistent with cHP) when BAL lymphocy-
tosis was >40%28. While Salisbury et al.24 proposed a 20%–30% 
threshold in their diagnostic model, which is mostly focused 
on cHPs.
The integration of the information conveyed by clinical his-
tory, lab tests, PFTs, HRCT, BAL analysis, and histology should 
be processed and discussed by MDTs in order to decide the 
best diagnostic strategy and reach a confident diagnosis. The 
importance of MDTs is growing constantly in the ILD field 
and the evidence-based algorithm proposed by Salisbury 
et al.24 takes the move from an MDT evaluation and wisely 
proposes a pathway that aims to reach the highest diagnostic 
confidence using the less amount of invasive procedures pos-
sible. 
Treatment
1. Antigen avoidance and immunosuppressants
Guidelines for HP treatment are not available at the mo-
ment. All the therapeutic regimens proposed to derive mostly 
from observational studies and very few randomized trials. 
The recognition of the inciting antigen is useful not only for 
diagnostic purposes but also for patients’ management. HP is 
recognized as a condition driven by a massive autoimmune 
response to inhaled antigens, then the first step of HP treat-
ment is the antigens’ avoidance, when possible. This is mostly 
effective in the early/acute phases of disease and less effec-
tive in the chronic forms of HP, when fibrotic changes inter-
vene27,69,75,76. Furthermore, in cHP fibrosis may progress even if 
the subjects are not exposed to the antigens anymore.
Another cornerstone of HP treatment is immunosuppres-
sant treatment, for the same reason. 
Corticosteroid treatment in HP is supported by weak evi-
dence. There is just one randomized trial and it is short and 
small77. The use of predinosolone tapered along 8 weeks 
against placebo was evaluated in cohort of 36 patients af-
fected by Farmer’s Lung. All the patients avoided contact with 
farms for the duration of the study. No differences were found 
in pulmonary function parameters, besides a significant dif-
ference in TLco. There was also no effect of corticosteroid 
treatment on mortality. Corticosteroids seem to be more ef-
fective on aHP when the phlogistic process is more abundant. 
Some other non-randomized trials and observational studies 
supported these findings75,76. De Sadeleer et al.76, in their ret-
rospective study, showed that the steroid treatment had no 
benefit on cHP patients, while it was effective on lung function 
and mortality of aHP patients. 
Other immunosuppressant therapies have been studied 
in HP patients, such as mycophenolate mofetil (MMF) and 
azathioprine (AZA)78,79. Both treatment regimens seemed 
to be effective improving TLco in cHP patients in the study 
of Morisset et al.78, not showing any benefit on survival. The 
study conducted by Adegunsoye et al.79, instead, did not show 
any effect of both AZA and MMF on lung function. Neverthe-
less, cHP patients who needed to undergo immunosuppres-
sant therapies showed a worse survival rate. However, an 
early transition to steroid-sparing drugs seems to reduce the 
incidence of treatment-emergent adverse events79. Rituximab 
is also sometimes used off-label as salvage treatment in refrac-
tory forms of cHP80.
Inhaled corticosteroid therapy is used on anecdotal basis81.
2. Antifibrotics and future perspectives
The prototype of the progressive fibrosing phenotype ILD is 
IPF, but this phenotype also develops in cHP. No matter what 
Table 1. Clinical trials exploring anti-fibrotic drugs’ role in cHP therapy
Agent Registration No. Study design Population Aims Primary end point State
Nintedanib NCT02999178 
(INBUILD)
Phase III, randomized, 
double blind, placebo-
controlled
Fibrosing ILDs Efficacy and 
safety




Pirfenidone NCT02496182 Phase II/III, placebo-
controlled, open-label, 
proof of concept 
cHP Efficacy and 
safety






Phase II, randomized, 
double blind, placebo-
controlled
cHP Efficacy and 
safety
Absolute change in % 
FVC from baseline 
to week 48
Completed
Pirfenidone NCT02958917 Phase II, randomized, 
double blind, placebo-
controlled
cHP Efficacy and 
Safety
Mean change in % 
FVC from baseline 
to week 52 
Ongoing
cHP: chronic hypersensitivity pneumonitis; ILDs: interstitial lung diseases; FVC: forced vital capacity.
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the lung injury causing agent is, fibrotic ILDs show similarities 
in disease presentation, behavior and also in the pathogenic 
process underlying the fibrotic process (Figure 1), which 
usually drives to irreversible loss of epithelial or endothelial 
barrier integrity, destruction of the lung architecture and loss 
of lung function82. Some authors took the moves from this 
assumption to test effectiveness of anti-fibrotic drugs in this 
cluster of diseases (Table 1). 
Recently the results of phase III randomized placebo-con-
trolled clinical trial—the INBUILD study (NCT02999178)—
were released and opened the doors to the safe use of nint-
edanib, an intracellular tyrosine kinase inhibitor, for fibrosing 
ILDs83. Flaherty et al.83 showed that nintedanib was effective 
in reducing the annual rate of FVC decline when compared 
to placebo in a cohort of 663 subjects. Patients with cHP rep-
resented 26% of the enrolled population, turning this a funda-
mental study for the management of this condition.
An open-label proof of concept study (NCT02496182) ex-
plored the efficacy of pirfenidone as add-on therapy to immu-
nosuppressant in cHP84. Besides not showing improvement 
of lung function test parameters, there was a significant St. 
George Respiratory Questionnaire’s total score improvement 
in the pirfenidone group. Addition of pirfenidone seems to 
have a tolerable safety profile and promising results in cHP 
patients.
Some other randomized clinical trials (RCT) exploring 
the effects of pirfenidone on cHP are on their way. A phase II 
placebo-controlled randomized controlled trial—the RELIEF 
study (EudraCT 2014–000861-32 DRKS00009822)—will soon 
explore the efficacy of pirfenidone in fibrosing ILDs and cHP 
is recognized as one of the inclusion criteria. Another phase II 
study (NCT02958917) is going to explore the effect of full dose 
pirfenidone in cHP patients85.
Lung transplant may be a resolutive treatment in cHP at its 
last stages of disease, such as in other ILDs. 
Conclusion
HP remains a challenging condition to diagnose and man-
age because of its heterogenous clinical, radiologic, histologic 
and functional features. Lots of efforts are put in making order 
in the ILD field, but HP remains still a foggy region—even if it 
is the third most common ILD. 
Even if in the last decade the interest around HP was con-
stantly growing, neither internationally accepted classification 
nor guidelines based on international consensus for both di-
agnosis and clinical management are available for this disease. 
Several classification proposals and diagnostic models were 
advanced by different groups but still have not received any 
prospective validation. The scientific community is anxiously 
waiting for the guidelines supported by the ATS and ACCP 
that are on the line and would facilitate the design of the next 
clinical studies. 
Diagnosis is particularly tricky in the latest stages of cHP 
when it may be confounded with IPF also in expert contests. 
MDT meetings play a pivotal role both in the diagnostic pro-
cess and in the decision making and patient management. 
Immunosuppressant therapy, which—together with antigen 
avoidance—is effective on aHP, is now flanked by the evidence 
of the effectiveness of nintedanib in reducing the rate of lung 
function decline in cHP. Other studies about pirfenidone use 
in HP are ongoing. 
However, several questions about this condition remain still 
unanswered and there is plenty of room for more studies to 
come and focus their attention on different aspects and pitfalls 
of HP. 
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